China Cancer Immunotherapy Drug Discovery Outsourcing Market Size & Outlook
China cancer immunotherapy drug discovery outsourcing market, 2018-2030 (US$M)
Related Markets
China cancer immunotherapy drug discovery outsourcing market highlights
- The China cancer immunotherapy drug discovery outsourcing market generated a revenue of USD 77.5 million in 2021 and is expected to reach USD 220.9 million by 2030.
- The China market is expected to grow at a CAGR of 12.3% from 2022 to 2030.
- In terms of segment, monoclonal antibodies was the largest revenue generating drug type in 2021.
- Cancer Vaccines and Oncolytic Viral Therapy is the most lucrative drug type segment registering the fastest growth during the forecast period.
Cancer immunotherapy drug discovery outsourcing market data book summary
| Market revenue in 2021 | USD 77.5 million |
| Market revenue in 2030 | USD 220.9 million |
| Growth rate | 12.3% (CAGR from 2021 to 2030) |
| Largest segment | Monoclonal antibodies |
| Fastest growing segment | Cancer Vaccines and Oncolytic Viral Therapy |
| Historical data | 2018 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Monoclonal Antibodies, Immunomodulators, Cancer Vaccines and Oncolytic Viral Therapy |
| Key market players worldwide | Labcorp Holdings Inc, PerkinElmer, WuXi Biologics (Cayman) Inc, Genscript Biotech Corp Class H, Eurofins Scientific SE, Personalis Inc, Explicyte, Aquila BioMedical, Crown Bioscience, Promega, Beach Energy Ltd, Celentyx, Nexelis, STC Biologics, Life Molecular Imaging |
Other key industry trends
- In terms of revenue, China accounted for 7.4% of the global cancer immunotherapy drug discovery outsourcing market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China cancer immunotherapy drug discovery outsourcing market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 160.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Immunotherapy Drug Discovery Outsourcing Market Scope
Cancer Immunotherapy Drug Discovery Outsourcing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China cancer immunotherapy drug discovery outsourcing market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cancer immunotherapy drug discovery outsourcing market will help companies and investors design strategic landscapes.
Monoclonal antibodies was the largest segment with a revenue share of 64.77% in 2021. Horizon Databook has segmented the China cancer immunotherapy drug discovery outsourcing market based on monoclonal antibodies, immunomodulators, cancer vaccines and oncolytic viral therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to China cancer immunotherapy drug discovery outsourcing market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China cancer immunotherapy drug discovery outsourcing market databook
-
Our clientele includes a mix of cancer immunotherapy drug discovery outsourcing market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China cancer immunotherapy drug discovery outsourcing market , including forecasts for subscribers. This country databook contains high-level insights into China cancer immunotherapy drug discovery outsourcing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
China cancer immunotherapy drug discovery outsourcing market outlook size, by drug type, 2018-2030 (US$M)
China Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook Share, 2021 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
